Point-of-care CD4 testing to inform selection of antiretroviral medications in South African antenatal clinics: A cost-effectiveness analysis

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Ciaranello, Andrea L ^a   Myer, Landon ^c   Kelly, Kathleen ^a   Christensen, Sarah ^a   Daskilewicz, Kristen ^c   Doherty, Katie ^a   Bekker, Linda Gail ^c   Hou, Taige ^a   Wood, Robin ^c   Francke, Jordan A ^a   Wools Kaloustian, Kara ^d   Freedberg, Kenneth A ^a,e,f   Walensky, Rochelle P ^a,b,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD UNIVERSITY   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS LOPINAVIR PLUS RITONAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS LOPINAVIR PLUS RITONAVIR PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INTERMETHOD COMPARISON; LABORATORY TEST; LIFE EXPECTANCY; MOTHER TO CHILD HIV TRANSMISSION; POINT OF CARE TESTING; PRACTICE GUIDELINE; PREGNANT WOMAN; PRENATAL CARE; SENSITIVITY AND SPECIFICITY; SOUTH AFRICAN; VIRUS TRANSMISSION; WEANING; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; HIV INFECTIONS; POINT OF CARE SYSTEM; PREGNANCY; PREVENTION AND CONTROL; PROCEDURES; SOUTH AFRICA; TRANSMISSION; VERTICAL TRANSMISSION; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LIFE EXPECTANCY; POINT-OF-CARE SYSTEMS; PREGNANCY; SOUTH AFRICA; YOUNG ADULT; ZIDOVUDINE;

EID: 84959289608     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117751     Document Type: Article

References (83)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2013) UNAIDS report on the global AIDS epidemic. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf. Accessed 2014 June 22.
2. Rollins N, Mahy M, Becquet R, Kuhn L, Creek T, et al. (2012) Estimates of peripartum and postnatal mother-to-child transmission probabilities of HIV for use in Spectrum and other population-based models. Sex Transm Infect 88 Suppl 2: i44-51. doi: 10.1136/sextrans-2012-050709 PMID: 23172345
3. World Health Organization (2010) Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. Geneva, Switzerland: WHO Press. Available: http://whqlibdoc.who.int/publications/2010/9789241599818-eng.pdf. Accessed 2014 July 14.
4. World Health Organization (2013) Consolidated guidelines on the use of antiretrovirals for the treatment and prevention of HIV infection. Available: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html. Accessed 2014 July 24.
5. South Africa National Department of Health (2010) Clinical Guidelines: PMTCT (Prevention of Motherto-Child Transmission). Available: http://www.fidssa.co.za/images/PMTCT-Guidelines.pdf. Accessed 2014 July 12.
6. South African Department of Health (2013) The South African Antiretroviral Treatment Guidelines. South Africa: South African Department of Health. Available: http://www.doh.gov.za/docs/policy/2013/ART-Treatment-Guidelines-Final-25March2013.pdf. Accessed 2014 July 3.
7. Ahmed S, Kim MH, Abrams EJ (2013) Risks and benefits of lifelong antiretroviral treatment for pregnant and breastfeeding women: a review of the evidence for the Option B+ approach. Curr Opin HIV AIDS 8: 474-489. doi: 10.1097/COH.0b013e328363a8f2 PMID: 23925003
8. Carter RJ, Dugan K, El-Sadr WM, Myer L, Otieno J, et al. (2010) CD4+ cell count testing more effective than HIV disease clinical staging in identifying pregnant and postpartum women eligible for antiretroviral therapy in resource-limited settings. J Acquir Immune Defic Syndr 55: 404-410. doi: 10.1097/QAI. 0b013e3181e73f4b PMID: 20595905
9. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, et al. (2008) Low rates of mother-tochild transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 22: 973-981. doi: 10.1097/QAD.0b013e3282f9b67a PMID: 18453857
10. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, et al. (2008) Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 22: 289-299. PMID: 18097232
11. Chibwesha CJ, Giganti MJ, Putta N, Chintu N, Mulindwa J, et al. (2011) Optimal time on HAART for prevention of mother-to-child transmission of HIV. J Acquir Immune Defic Syndr 58: 224-228. doi: 10. 1097/QAI.0b013e318229147e PMID: 21709566
12. Fitzgerald FC, Bekker LG, Kaplan R, Myer L, Lawn SD, et al. (2010) Mother-to-child transmission of HIV in a community-based antiretroviral clinic in South Africa. S Afr Med J 100: 827-831. PMID: 21414276
13. Stinson K, Boulle A, Coetzee D, Abrams EJ, Myer L (2010) Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa. Trop Med Int Health 15: 825-832. doi: 10. 1111/j.1365-3156.2010.02538.x PMID: 20497405
14. Myer L, Zulliger R, Black S, Pienaar D, Bekker LG (2012) Pilot programme for the rapid initiation of antiretroviral therapy in pregnancy in Cape Town, South Africa. AIDS Care 24: 986-992. doi: 10.1080/09540121.2012.668173 PMID: 22519561
15. Myer L, Daskilewicz K, McIntyre J, Bekker LG (2013) Comparison of point-of-care versus laboratorybased CD4 cell enumeration in HIV-positive pregnant women. J Int AIDS Soc 16: 18649. doi: 10.7448/IAS.16.1.18649 PMID: 24044627
16. Jani IV, Sitoe NE, Alfai ER, Chongo PL, Quevedo JI, et al. (2011) Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet 378: 1572-1579. doi: 10.1016/S0140-6736(11)61052-0 PMID: 21951656
17. Larson B, Schnippel K, Ndibongo B, Xulu T, Brennan A, et al. (2012) Rapid point-of-care CD4 testing at mobile HIV testing sites to increase linkage to care: an evaluation of a pilot program in South Africa. J Acquir Immune Defic Syndr 61: e13-17. PMID: 22659650
18. Mnyani CN, McIntyre JA, Myer L (2012) The reliability of point-of-care CD4 testing in identifying HIV-infected pregnant women eligible for antiretroviral therapy. J Acquir Immune Defic Syndr 60: 260-264. doi: 10.1097/QAI.0b013e318256b651 PMID: 22487589
19. Glencross DK, Coetzee LM, Faal M, Masango M, Stevens WS, et al. (2012) Performance evaluation of the Pima point-of-care CD4 analyser using capillary blood sampling in field tests in South Africa. J Int AIDS Soc 15: 3. doi: 10.1186/1758-2652-15-3 PMID: 22284546
20. Jani IV, Sitoe NE, Quevedo JI, Lehe JD, Peter TF. Cost comparison of point-of-care and laboratory CD4 testing in resource-limited settings. Abstract #MOAD0101; 2011; Rome, Italy. Available: http://pag.ias2011.org/abstracts.aspx?aid=4201. Accessed 2014 May 1.
21. Larson B, Schnippel K, Ndibongo B, Long L, Fox MP, et al. (2012) How to estimate the cost of point-ofcare CD4 testing in program settings: an example using the Alere Pima Analyzer in South Africa. PLoS One 7: e35444. doi: 10.1371/journal.pone.0035444 PMID: 22532854
22. Cleary S, Chitha W, Jikwana S, Okorafor OA, Boulle A (2005) Health Systems Trust: South African Health Review. Durban. Available: http://www.healthlink.org.za/publications/682. Accessed 2014 July 1.
23. Myer L (2013) Personal communication regarding treatment data at the Hanover Park Midwife Obstetrics Unit.
24. Clinton Health Access Initiative (2012) Antiretroviral (ARV) Ceiling Price List. Available: http://d2pd3b5abq75bb.cloudfront.net/2012/07/12/15/03/07/163/CHAI-ARV-Ceiling-Price-List-May-2012.pdf. Accessed 2014 July 18.
25. Ciaranello AL, Perez F, Engelsmann B, Walensky RP, Mushavi A, et al. (2013) Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. Clin Infect Dis 56: 430-446. doi: 10.1093/cid/cis858 PMID: 23204035
26. Ciaranello A, Perez F, Keatinge J, Park J, Engelsmann B, et al. (2012) What will it take to eliminate pediatric HIV? Reaching "virtual elimination" targets for prevention of mother-to-child HIV transmission (PMTCT) in Zimbabwe. PLoS Med 9: e1001156. doi: 10.1371/journal.pmed.1001156 PMID: 22253579
27. Ciaranello AL, Perez F, Maruva M, Chu J, Englesmann B, et al. (2011) WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: Modeling clinical outcomes in infants and mothers. PLoS ONE 6: e20224. doi: 10.1371/journal.pone.0020224 PMID: 21655097
28. Ciaranello A, Lockman S, Freedberg KA, Hughes M, Chu J, et al. (2011) First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS 25: 479-492. doi: 10.1097/QAD.0b013e3283428cbe PMID: 21293199
29. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, et al. (2006) Cost-effectiveness of HIV treatment in resource-poor settings-the case of Côte d'Ivoire. N Engl J Med 355: 1141-1153. PMID: 16971720
30. Ciaranello AL, Morris BL, Walensky RP, Weinstein MC, Ayaya S, et al. (2013) Validation and calibration of a computer simulation model of pediatric HIV infection. PLoS ONE 8: e83389. doi: 10.1371/journal. pone.0083389 PMID: 24349503
31. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors (1996) Cost-effectiveness in health and medicine. New York: Oxford University Press.
32. World Health Organization (2010) WHO-CHOICE: Cost-effectiveness thresholds. Available: www.who. int/choice/costs/CER-thresholds/en/index.html. Accessed 2014 July 13.
33. International Monetary Fund (IMF) (2014) World Economic Outlook Database. Available: http://www.imf.org/external/ns/cs.aspx?id = 28. Accessed 2014 July 20.
34. Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, et al. (2009) When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 151: 157-166. PMID: 19620143
35. Holmes CB, Wood R, Badri M, Zilber S, Wang B, et al. (2006) CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 42: 464-469. PMID: 16810113
36. Ciaranello AL, Lu Z, Ayaya S, Losina E, Musick B, et al. (2014) Incidence of WHO Stage 3 and 4 events, tuberculosis, and mortality in untreated, HIV-infected children enrolling in care before 1 year of age: an IeDEA (International Epidemiologic Databases to Evaluate AIDS) East Africa regional analysis. Pediatr Infect Dis J 33: 623-629. doi: 10.1097/INF.0000000000000223 PMID: 24378935
37. South Africa National Department of Health (2010) Antiretroviral Treatment Guidelines. Available: http://www.uj.ac.za/EN/CorporateServices/ioha/Documentation/Documents/ART%20Guideline.pdf. Accessed 2014 July 11.
38. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents-Recommendations for a public health approach. Available: http://www.who.int/hiv/pub/arv/adult2010/en/index.html. Accessed 2014 July 2.
39. South African National Department of Health (2010) Guidelines for the management of HIV in children. Available: http://www.sahivsoc.org/upload/documents/Guidelines-for-Management-of-HIV-in-Children-2010.pdf. Accessed 2014 July 20.
40. Coetzee D, Hildrebrand K, Boulle A, Maartens G, Louis F, et al. (2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18: 887-895. PMID: 15060436
41. Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, et al. (2010) Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 363: 1499-1509. doi: 10.1056/NEJMoa0906626 PMID: 20942666
42. Stringer JS, McConnell MS, Kiarie J, Bolu O, Anekthananon T, et al. (2010) Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study. PLoS Med 7: e1000233. doi: 10.1371/journal.pmed.1000233 PMID: 20169113
43. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, et al. (2012) Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 366: 2380-2389. doi: 10.1056/NEJMoa1113249 PMID: 22716976
44. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, et al. (2010) Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 363: 1510-1520. doi: 10.1056/NEJMoa1000931 PMID: 20942667
45. Black S, Zulliger R, Myer L, Marcus R, Jeneker S, et al. (2013) Safety, feasibility and efficacy of a rapid ART initiation in pregnancy pilot programme in Cape Town, South Africa. S Afr Med J 103: 557-562. doi: 10.7196/samj.6565 PMID: 23885739
46. Anglaret X, Chene G, Attia A, Toure S, Lafont S, et al. (1999) Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 353: 1463-1468. PMID: 10232311
47. Thomas LS (2006) Costing of HIV/AIDS services at a tertiary level hospital in Gauteng Province. Faculty of Health Sciences, University of Witwatersrand, South Africa. Available: http://wiredspace.wits.ac. za/handle/10539/2008. Accessed 2014 May 6.
48. UNITAID (2014) HIV/AIDS Diagnostics Technology Landscape. Available: http://www.unitaid.org/images/marketdynamics/publications/UNITAID-HIV-Diagnostic-Landscape-4th-edition.pdf. Accessed 2014 October 20.
49. Palamountain KM, Baker J, Cowan EP, Essajee S, Mazzola LT, et al. (2012) Perspectives on introduction and implementation of new point-of-care diagnostic tests. J Infect Dis 205 Suppl 2: S181-190. doi: 10.1093/infdis/jis203 PMID: 22402038
50. Thairu L, Katzenstein D, Israelski D (2011) Operational challenges in delivering CD4 diagnostics in sub-Saharan Africa. AIDS Care 23: 814-821. doi: 10.1080/09540121.2010.541416 PMID: 21400312
51. UNAIDS (2012) Report on the global AIDS epidemic Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120-UNAIDS-Global-Report-2012-en.pdf. Accessed 2014 July 18.
52. Goga A, Dinh TH, Jackson D, Lombard C, Crowley S, et al. (2012) Impact of the national prevention of mother-to-child transmission of HIV (PMTCT) program on perinatal mother-to-child transmission of HIV (MTCT) measured at six weeks postpartum, South Africa (SA): results of the first year of implementation of the 2010 P (Abstract no. WEPE173); Washington, D.C. Available: http://www.iasociety.org/Default.aspx?pageId=11&abstractId=200745035. Accessed 2014 June 17.
53. World Health Organization (2012) Programmatic update: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Available: http://www.who.int/hiv/pub/mtct/programmatic-update2012/en/. Accessed 2014 July 15.
54. Schouten EJ, Jahn A, Midiani D, Makombe SD, Mnthambala A, et al. (2011) Prevention of motherto-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet 378: 282-284. doi: 10.1016/S0140-6736(10)62303-3 PMID: 21763940
55. Jani IV, Sitoe NE, Chongo PL, Alfai ER, Quevedo JI, et al. (2011) Accurate CD4 T-cell enumeration and antiretroviral drug toxicity monitoring in primary healthcare clinics using point-of-care testing. AIDS 25: 807-812. doi: 10.1097/QAD.0b013e328344f424 PMID: 21378535
56. Balakrishnan P, Iqbal HS, Shanmugham S, Mohanakrishnan J, Solomon SS, et al. (2011) Low-cost assays for monitoring HIV infected individuals in resource-limited settings. Indian J Med Res 134: 823-834. doi: 10.4103/0971-5916.92628 PMID: 22310816
57. Walker AS, Gibb DM (2011) Monitoring of highly active antiretroviral therapy in HIV infection. Curr Opin Infect Dis 24: 27-33. doi: 10.1097/QCO.0b013e3283423e0e PMID: 21150591
58. World Health Organization Department of Maternal, Newborn, Child and Adolescent Health (2014) Does provision of point of care CD4 technology and early knowledge of CD4 levels affect early initiation and retention on anti-retroviral (ART) in HIV positive pregnancy women in the context of Option B+ for PMTCT? Available: http://www.clinicaltrials.gov/ct2/show/NCT02070900. Accessed 2014 July 9.
59. Kellerman SE, Ahmed S, Feeley-Summerl T, Jay J, Kim M, et al. (2013) Beyond prevention of motherto-child transmission: keeping HIV-exposed and HIV-positive children healthy and alive. AIDS 27 Suppl 2: S225-233. doi: 10.1097/QAD.0000000000000107 PMID: 24361632
60. World Health Organization (2010) New guidance on prevention of mother-to-child transmission of HIV and infant feeding in the context of HIV. Available: http://www.who.int/hiv/pub/mtct/PMTCTfactsheet/en/index.html. Accessed 2014 July 12.
61. Kesho Bora Study Group (2011) Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 1: 159.
62. Kesho Bora Study Group (2012) Maternal HIV-1 disease progression 18-24 months postdelivery according to antiretroviral prophylaxis regimen (triple-antiretroviral prophylaxis during pregnancy and breastfeeding vs zidovudine/single-dose nevirapine prophylaxis): The Kesho Bora randomized controlled trial. Clin Infect Dis 55: 449-460. doi: 10.1093/cid/cis461 PMID: 22573845
63. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, et al. (1994) Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 331: 1173-1180. PMID: 7935654
64. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, et al. (2010) Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 362: 2282-2294. doi: 10.1056/NEJMoa0907736 PMID: 20554983
65. National Institutes of Health: IMPAACT Trial Network (2012) The PROMISE Study (Promoting Maternal and Infant Survival Everywhere): Examining Benefits of HAART Continuation in Postpartum Mothers. Available: http://clinicaltrials.gov/show/NCT00955968. Accessed 3 July 2014.
66. Gopalappa C, Stover J, Shaffer N, Mahy M (2014) The costs and benefits of Option B+ for the prevention of mother-to-child transmission of HIV. AIDS 28 Suppl 1: S5-14. doi: 10.1097/QAD. 0000000000000083 PMID: 24468947
67. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505. doi: 10.1056/NEJMoa1105243 PMID: 21767103
68. Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, et al. (2013) Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. The New England journal of medicine 369: 1715-1725. doi: 10.1056/NEJMsa1214720 PMID: 24171517
69. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, et al. (2012) Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health 15: 835-842. doi: 10.1016/j.jval.2012.04.014 PMID: 22999133
70. Stinson K, Myer L (2012) Barriers to initiating antiretroviral therapy during pregnancy: a qualitative study of women attending services in Cape Town, South Africa. African Journal of AIDS Research 11: 65-73.
71. Hoffman RM, Black V, Technau K, van der Merwe KJ, Currier J, et al. (2010) Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa. J Acquir Immune Defic Syndr 54: 35-41. doi: 10.1097/QAI.0b013e3181cf9979 PMID: 20216425
72. Department of Health Republic of South Africa (2012) Saving mothers 2008-2010: fifth report on the confidential enquiries into maternal deaths in South Africa- short report.
73. Dabis F, Bequet L, Ekouevi DK, Viho I, Rouet F, et al. (2005) Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 19: 309-318. PMID: 15718842
74. Thior I, Lockman S, Smeaton LM, Shapiro RL, Wester C, et al. (2006) Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce motherto-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 296: 794-805. PMID: 16905785
75. Kilewo C, Karlsson K, Ngarina M, Massawe A, Lyamuya E, et al. (2009) Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr 52: 406-416. doi: 10.1097/QAI.0b013e3181b323ff PMID: 19730269
76. Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, et al. (2007) Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med 4: e257. PMID: 17713983
77. Peltier CA, Ndayisaba GF, Lepage P, van Griensven J, Leroy V, et al. (2009) Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda. AIDS 23: 2415-2423. doi: 10.1097/QAD.0b013e32832ec20d PMID: 19730349
78. Palombi L, Marazzi MC, Voetberg A, Magid NA (2007) Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS 21 Suppl 4: S65-71. PMID: 17620755
79. Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, et al. (2010) Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 362: 2271-2281. doi: 10.1056/NEJMoa0911486 PMID: 20554982
80. Vyankandondera J, Luchters S, Hassink E. (2003) Reducing risk of HIV-1 transmission from mother to infant through breastfeeding using antiretroviral prophylaxis in infants (SIMBA-study, Abstract NoLB7); Paris, France. Available: http://www.iasociety.org/Default.aspx?pageId=11&abstractId=11061. Accessed 2014 May 22.
81. Thomas TK, Masaba R, Borkowf CB, Ndivo R, Zeh C, et al. (2011) Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding-the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med 8: e1001015. doi: 10.1371/journal.pmed.1001015 PMID: 21468300
82. World Health Organization (2010) Antiretroviral therapy for HIV infection in infants and children: Recommendations for a public health approach.
83. Vander Plaetse B, Hlatiwayo G, Van Eygen L, Meessen B, Criel B (2005) Costs and revenue of health care in a rural Zimbabwean district. Health Policy Plan 20: 243-251. PMID: 15965036